Get the Stockscreener App
8.39
5.73%
-0.51
After Hours:
8.37
-0.02
-0.24%
Personalis Inc stock is traded at $8.39, with a volume of 1.24M.
It is down -5.73% in the last 24 hours and down -2.10% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$8.90
Open:
$8.98
24h Volume:
1.24M
Relative Volume:
0.84
Market Cap:
$745.07M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.7289
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+13.15%
1M Performance:
-2.10%
6M Performance:
+83.59%
1Y Performance:
+80.04%
1-Day Range:
$7.95
$9.0364
1-Week Range:
$7.581
$9.0364
52-Week Range:
$2.8262
$11.50
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.39 | 790.36M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
509.82 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
214.94 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
617.20 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
124.88 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
319.83 | 32.29B | 3.17B | 642.63M | 539.81M | 10.77 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results - BioSpace
Personalis Data Breach Potentially Exposes PII and PHI - Claim Depot
Medicare Now Covers NeXT Personal® MRD Testing for Lung Cancer SurveillancePersonalis, Inc. - Oncodaily
Personalis (NASDAQ:PSNL) Price Target Raised to $13.00 - MarketBeat
Medicare approves Personalis’ lung cancer test for surveillance By Investing.com - Investing.com Canada
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Investment Magazine
Personalis (PSNL) Gains 10% Following Medicare Coverage for Canc - GuruFocus
Personalis (NASDAQ:PSNL) Shares Gap UpShould You Buy? - MarketBeat
Personalis wins Medicare coverage for NeXT Personal (PSNL) - Seeking Alpha
Personalis stock rises after Medicare approves lung cancer test coverage - Investing.com
Why Is Personalis Stock Soaring Tuesday?Personalis (NASDAQ:PSNL) - Benzinga
Why Personalis Stock Is Rising: Medicare Covers Lung Cancer MRD Test - Stocktwits
Personalis rises as Medicare extends coverage to lung cancer test - TradingView
Personalis Inc receives Medicare coverage for Next Personal in lung cancer surveillance - marketscreener.com
Personalis Inc Receives Medicare Coverage For Next Personal In Lung Cancer Surveillance - TradingView
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer Surveillance - Business Wire
Revenue Check: Can Personalis Inc stock double in the next yearJuly 2025 Reactions & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Wellington Shields Capital Management LLC Cuts Stake in Personalis, Inc. $PSNL - MarketBeat
Breakthrough Cancer Monitoring Technique Fuels Growth for Personalis - AD HOC NEWS
Aug Final Week: Is Personalis Inc showing insider buyingLong Setup & AI Enhanced Trading Signals - baoquankhu1.vn
Personalis, Inc. (PSNL): A Bull Case Theory - Yahoo Finance
Personalis (PSNL) Study Highlights NeXT Personal's Impact in Can - GuruFocus
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid Tumors - Business Wire
Personalis, Inc. (PSNL) Stock Analysis: A 11.76% Potential Upside Amidst Revenue Challenges - DirectorsTalk Interviews
Wall Street Zen Upgrades Personalis (NASDAQ:PSNL) to Hold - MarketBeat
Is Personalis Inc.’s growth already priced inJuly 2025 Recap & Consistent Return Strategy Ideas - mfd.ru
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - BioSpace
Insider Selling: Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - Defense World
What 9 Analyst Ratings Have To Say About Personalis - Benzinga
Guggenheim Raises Price Target for Personalis (PSNL) to $13.00 | - GuruFocus
Gainers Report: Is Personalis Incs growth already priced inShare Buyback & Entry Point Strategy Guides - baoquankhu1.vn
Personalis (NASDAQ:PSNL) Sets New 12-Month High – Still a Buy? - Defense World
Hedge Fund Bets: Should you avoid Personalis Inc stock right nowEarnings Risk Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Personalis, Inc. $PSNL Shares Purchased by AIGH Capital Management LLC - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares By Investing.com - Investing.com Nigeria
Personalis (NASDAQ:PSNL) CFO Sells $13,811.50 in Stock - MarketBeat
Personalis CFO Tachibana sells $13,811 in shares - Investing.com
Personalis (NASDAQ:PSNL) Reaches New 12-Month HighWhat's Next? - MarketBeat
Personalis Sees Revised Reimbursement Rates for Cancer Tests - MSN
Personalis (NASDAQ:PSNL) Trading 14.8% HigherStill a Buy? - MarketBeat
Aug Swings: Can Personalis Inc stock double in the next yearJuly 2025 Sector Moves & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Market Rankings: How does PLRX perform in inflationary periodsWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
How A New Price Target Is Shaping The Evolving Story For Personalis (PSNL) - Yahoo Finance
Winners Losers: Is Personalis Incs growth already priced inDollar Strength & Risk Controlled Daily Plans - baoquankhu1.vn
Personalis, Inc. (NASDAQ:PSNL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Trading Action: Can Personalis Inc grow without external fundingJuly 2025 Volume & Weekly High Return Stock Forecasts - baoquankhu1.vn
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable - simplywall.st
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Personalis, Inc. (PSNL) Stock Analysis: A Promising 14.46% Upside Potential Amid Strategic Collaboration - DirectorsTalk Interviews
Aug Closing: Is Personalis Inc a defensive stockMarket Volume Report & Technical Pattern Recognition Alerts - baoquankhu1.vn
Aug Technicals: Is Personalis Inc showing insider buyingRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):